CN-121975696-A - Saliva combined lactobacillus and application thereof

Abstract

The invention belongs to the technical field of microorganisms, and particularly relates to a salivary combined lactobacillus and application thereof. Through a large number of screening and verification tests, the invention discloses a saliva combined lactobacillus 194-07 (Ligilactobacillus salivarius 194-07) with strong growth activity, which can inhibit DPP4 activity, can obviously improve the movement of the central area of a mouse open field and the expression in the movement of an elevated plus maze in an anxiety disorder mouse model, can improve the neurotransmitter level of the mouse, can inhibit the inflammatory factor level in vivo and in-brain hippocampus tissues, and has good safety. The strain has good application potential in aspects of blood sugar control, mental diseases (anxiety disorder), nerve inflammation resistance and the like.

Inventors

• LI ZHONGXIA
• HE RUIKUN
• CHEN XU
• MENG XIAOJING
• ZE XIAOLEI
• Di Can
• YU WEIJIAN
• PANG YUAN
• WANG DI
• SHANG KE

Assignees

• 汤臣倍健股份有限公司

Dates

Publication Date

20260505

Application Date

20260210

Claims (10)

1. 1. The saliva combined lactobacillus is characterized in that the saliva combined lactobacillus is saliva combined lactobacillus 194-07 (Ligilactobacillus salivarius 194-07) and is preserved in the microorganism strain preservation center of Guangdong province in China, the preservation address is building 5 of No. 59 of the road 100 university in Xiuzhou martyr of Guangzhou province in Guangdong, the preservation number is GDMCC No:67301, and the preservation date is 2025, 11, 14 days.
2. 2. A probiotic preparation, characterized in that the preparation contains the saliva of claim 1 in combination with lactobacillus 194-07 or a fermentation product thereof.
3. 3. A composition comprising, in addition to the salivary lactobacillus 194-07 of claim 1, one or more of the group consisting of probiotics, prebiotics, dietary fibers, proteins, polypeptides, amino acids, lipids, carbohydrates, vitamins, minerals, and plant extracts.
4. 4. The composition of claim 3, wherein the probiotic is selected from the group consisting of bifidobacterium, lactobacillus mucilaginosus, lactobacillus plantarum, lactobacillus co-produced, lactobacillus guanfaciens, streptococcus, lactococcus, propionibacterium, leuconostoc, pediococcus, weisman mann's bacteria, zoococcus, staphylococcus, ackermannia, clostridium, or any combination thereof.
5. 5. The formulation according to claim 2 or the composition according to claim 3, wherein the content of lactobacillus salivarius 194-07 is greater than 10 6 CFU/g or greater than 10 6 CFU/mL.
6. 6. Use of lactobacillus salivarius 194-07 in combination as claimed in claim 1 in the manufacture of a food product, dietary nutritional supplement, pharmaceutical product.
7. 7. The use according to claim 6, wherein the dietary supplement, pharmaceutical product, is in a dosage form selected from the group consisting of tablets, capsules, gel candies, oral liquid formulations, pills, powders, drops.
8. 8. The use according to claim 6, wherein the food, dietary supplement, pharmaceutical product further comprises additives/adjuvants acceptable in food, dietary supplement, pharmaceutical product.
9. 9. The method according to claim 8, wherein the adjuvant comprises a filler, a binder, a lubricant, a glidant, a thickener, a flavoring agent, an edible oil, a stabilizer, a suspending agent, a surfactant, or any combination thereof.
10. 10. Use of the sialyl-lactobacillus 194-07 according to claim 1 for the preparation of a composition for the prevention and/or treatment of anxiety disorders and/or for the control of blood glucose, preferably the composition is a pharmaceutical product, a health food, a dietary nutritional supplement.

Description

Saliva combined lactobacillus and application thereof Technical Field The invention belongs to the technical field of microorganisms, and particularly relates to a salivary combined lactobacillus and application thereof. Background Anxiety disorder is a common chronic mental disease, has the characteristics of high mortality rate and high recurrence rate, seriously affects the quality of work and life, and brings great economic burden to individuals and society. Anxiety disorder is mainly manifested by excessive anxiety, insomnia, etc. The key mechanism of the anxiolytic drugs widely used in clinic, such as buspirone hydrochloride, fluoxetine hydrochloride and the like, relates to the specific regulation of a 5-hydroxytryptamine neurotransmitter system, thereby improving the nerve function. Although such drugs play an important role in the treatment of anxiety, side effects are also evident, such as headache, dizziness, nausea, diarrhea, sexual dysfunction, and abnormal blood pressure or weight. In addition, the higher treatment cost limits the application range, and is generally only used for patients with serious illness, but is not suitable for people with mild symptoms, and is also difficult to be used for anxiety disorder prevention of sensitive people. Therefore, the development of the product which has smaller side effect and more economic price and is suitable for the sensitive crowd to prevent anxiety disorder has important practical significance and clinical requirements. Anxiety and depression are two common mental disorders, but it will be appreciated by those skilled in the art that anxiety and depression are both common and distinct, anxiety is not equivalent to depression, although some depressed patients are accompanied by anxiety, which does not necessarily result in depression, and depression does not necessarily have anxiety. The method is characterized in that for anxiety disorder, the core emotion is fear, worry and tension, for feedback of result uncertainty, the feedback points to the future, the feedback is extremely uneasy to what does not happen yet, the body and the thinking are in a 'highly alert' state of war, the body energy is too high and can not be relaxed, the thinking activity is in a disastrous thinking and the thinking transition, and the main physiological and behavioral activities are palpitation, muscle tension, tremble, sweating, shortness of breath, gastrointestinal discomfort, difficulty in falling asleep, restlessness, avoidance-type behaviors and less suicide-related thoughts. The heart emotion of the depression is sadness, deficiency and invaluable, and points to the past and the present, the physical energy is low, the physical energy is full of lassitude, the thinking mode is mainly negative, pessimistic and mental retardation, the depression is in an energy exhaustion state, the sleep is too much or too little, the appetite is increased or reduced, the weight is obviously changed, and the social activity is obviously reduced and the depression is weak. From a molecular mechanical perspective, anxiety is an alarm system in which the body is overactive, the HPA axis (hypothalamic-pituitary-adrenal axis) is overactive, CRH and norepinephrine release are increased, ultimately leading to brain "amygdala" overactivity, while depressed patients' HPA axis function is exhausted, hippocampal atrophy and BDNF decrease occur, ultimately leading to reduced functional connectivity of the prefrontal cortex. In recent years, the research of the axis of 'microorganism-intestine-brain' provides a new view for preventing and treating mental diseases. There is evidence that intestinal microorganisms can be involved in the pathological processes of psychotic disorders by means of immunization, neuroendocrine and metabolism. Probiotics serve as active beneficial microorganisms, inhibit the colonization of harmful bacteria and promote the proliferation of beneficial bacteria through positive interaction with endogenous microbiota and intestinal cells, regulate the secretion and balance of various neurotransmitters, and participate in regulating the emotion and psychological state of the brain of a host. In addition, probiotics can also reduce the chronic inflammation level of the system and relieve the neuromorphic inflammation. However, the use of Lactobacillus salivarius in the prevention and treatment of psychotic disorders, in particular anxiety, has not been reported. Dipeptidyl peptidase-4 (DIPEPTIDYL PEPTIDASE-4, abbreviated as DPP 4) is a glycoprotein distributed on the cell surface, and one of its main functions is to hydrolyze and inactivate incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulin secretory peptide (GIP). DPP4 limits the physiological efficacy of GLP-1 in blood glucose regulation by specifically cleaving two amino acid residues in the GLP-1 molecule, rendering it inactive. In addition to GLP-1 and GIP, DPP4 can degrade a variety of